FOXO4-DRI
Also known as: FOXO4-D-Retro-Inverso, Proxofim
Molecular Identifiers
Overview
Senolytic peptide in the D-retro-inverso version of FOXO4, designed to selectively eliminate senescent cells. Uses D-amino acids in reversed sequence for resistance to proteolytic degradation. Acts by disrupting the FOXO4-p53 interaction that keeps senescent cells viable, inducing selective apoptosis of these cells.
D-retro-inverso peptide — all amino acids are D-enantiomers in reversed sequence for protease resistance
Half-life
~12-24 hours
Administration Route
Subcutaneous
Category
Specialized Research
Mechanism of Action
- Disruption of the FOXO4-p53 interaction in senescent cells
- Induction of selective apoptosis of senescent cells
- Release of p53 for activation of the mitochondrial apoptotic pathway
- Reduction of senescent cell burden and senescence-associated secretory phenotype (SASP)
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 5-10 mg per injection |
| Frequency | Every other day or per protocol |
| Timing | Morning |
| Duration | Variable — intermittent use in short cycles |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Temporary fatigue
- Gastrointestinal discomfort
- Mild muscle pain
Presentations & Preparation
Vials of FOXO4-DRI found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C or -20°C for long-term storage
- Reconstituted: Refrigerated 2-8°C (up to 14 days)
- Protect from direct light
- Do not freeze after reconstitution
- Sensitive peptide — maintain cold chain
Scientific Studies
Published studies on FOXO4-DRI.
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourgeois BRM, Stryeck S, Rijksen Y, et al.
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Huang Y, He Y, Makarcyzk MJ, Lin H
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
100-500 mcg per injection (subcutaneous) · Once daily
Bronchogen
5-10 mg per day via subcutaneous injection · Once daily
Cardiogen
5-10 mg per day subcutaneously · Once daily
Chonluten
5-10 mg per day subcutaneously · Once daily
Crystagen
5-10 mg per day via subcutaneous injection · Once daily